5.! Le! Gouill! S,! Beldi>Ferchiou! A,! Cacheux! V,! et! al.! Obinutuzumab! plus! DHAP! followed! by! ASCT! plus!
Obinutuzumab!maintenance!provides!a!high!MRD!response!rate!in!untreated!MCL!patients,!results!of!
the! LYMA>101! trial,! a! LYSA! group! study.! Abstract! S103.! 24th! European! Hematology! Association!
Congress,!Amsterdam,!NL.!2019!Jun!14.!
6.! Ladetto! M,! et! al.! Lenalidomide! maintenance! improves! MCL! survival! after! ASCT.! ASH! 2018.! Oral!
session.!!
7.! Dreyling! M,! Campo! E,! Hermine! O,! et! al.! Newly! Diagnosed! and! Relapsed! Mantle! Cell! Lymphoma:!
ESMO!Clinical!Practice!Guidelines.!Ann!Oncol!(2017)!28!(suppl!4):!iv62–iv71.!
8.!NCCN!Guidelines>!Mantle!Cell!Lymphoma.!Vers!April!2020.!!
9.! Ferrero! S,! Rossi! D,! Rinaldi! A! et! al.! KMT2D! mutations! and! TP53! disruptions! are! poor! prognostic!
biomarkers!in!mantle!cell!lymphoma!receiving!high>dose!therapy:!a!FIL!study.!Haematologica.!2019!
Sep!19.!pii:!haematol.2018.214056.!
10.!Romaguera!JE,!Fayad!L,!Rodriguez!MA,!et!al.!High!rate!of!durable!remissions!after!treatment!of!
newly!diagnosed!aggressive!mantle>cell!lymphoma!with!rituximab!plus!hyper>CVAD!alternating!with!
rituximab!plus!high>dose!methotrexate!and!cytarabine.!J!Clin!Oncol.!2005!Oct!1;23(28):7013>23.!
11.!Kamdar!M,!Hongli!Li,!Chen!RW,!et!al.!Five>year!outcomes!of!the!S1106!study!of!R>hyper>CVAD!vs!
R>bendamustine!in!transplant>eligible!patients!with!mantle!cell!lymphoma.!Blood!Adv.!2019!Oct!22;!
3(20):!3132–3135.!
12.! Scheffold! A,! Jebaraj! BMC,! Stilgenbauer! S.! Venetoclax:! targeting! BCL2! in! hematological! cancers.!
Recent!Results!Cancer!Res.!2018;!212:215–242.!
13.! Wang! M,! Lundry! Locke! F,! Munoz! J,! et! al.! ZUMA>2:! Phase! 2! multicenter! study! evaluating!
efficacy!of!kte>C19!in!patients!with!relapsed/refractory!mantle!cell!lymphoma.!Abstract.!J.!Cl.!Onco.!
2018.36.15,!suppl.!TPS!3102.!
14.! Goebeler!M.E.,!Knop!S.,!Viardot!A.,!et!al.!Bispecific!T>cell!engager!(BiTE)!antibody!construct!
blinatumomab!for!the!treatment!of!patients!with!relapsed/refractory!non>hodgkin!lymphoma:!final!
results!from!a!phase!I!study.!J.!Clin.!Oncol.!2016;34(10):1104–1111.!
15.! Wang! ML,! Rule! S,! Martin! P! et! al.! Targeting! BTK! with! ibrutinib! in! relapsed! or! refractory!
mantle>cell!lymphoma.!N!Engl!J!Med!2013;!369(6):507–16.!
16.! Toby! A.! Eyre,! Harriet! S.! Walter,! Sunil! Iyengar! et! al.! Efficacy! of! venetoclax! monotherapy! in!
patients! with! relapsed,! refractory! mantle! cell! lymphoma! after! Bruton! tyrosine! kinase! inhibitor!
therapy.!Haematologica.!2019!Feb;!104(2):!e68–e71.!
17.! Tam!CS,!Anderson!MA,!Pott!C,!et!al.!Ibrutinib!plus!venetoclax!for!the!treatment!of!mantle>cell!
lymphoma.!N!Engl!J!Med.!2018;378(13):1211–1223.!
18.! Song!Y,!Zhou!K,!Zou!D,!et!al.!Safety!and!activity!of!the!investigational!bruton!tyrosine!kinase!
inhibitor!zanubrutinib!(BGB>3111)!in!patients!with!mantle!cell!lymphoma!from!a!phase!2!trial.!Blood.!
2018;132((Supplement!1)):148.!doi:10.1182/blood>2018>99>117956!
19.! Wang! M,! Rule! S,! Zinzani! PL,! et! al.! Acalabrutinib! in! relapsed! or! refractory! mantle! cell!
lymphoma!(ACE>LY>004):!a!single>arm,!multicentre,!phase!2!trial.!Lancet.!2018;391:659–67.!
! !